Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
A multi-center, open-label, single-arm, phase I/II clinical study is designed to test the
safety and immunogenicity of an investigational Dendritic and Glioma Cells Fusion vaccine
given with IL-12 for treatment-naïve patients after resection of glioblastoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University